Seven of 13 big pharmas have combined buyback and dividend yields that are higher than aggregate yields for companies in the S&P 500 Index. Twelve pharmas have higher dividend yields than the S&P 500, while four have higher buyback yields. Data below based on stock repurchases and dividends paid for the trailing 12 months ended